Hampstead Private Capital

Hampstead Private Capital is a private investment firm that focuses on the life sciences, biotechnology, and healthcare sectors. It serves as a strategic investment vehicle, primarily associated with the Apeiron Investment Group and entrepreneur Christian Angermayer. The firm specializes in identifying and funding high-growth opportunities in transformative medical fields, including mental health, psychedelic medicine, and longevity. Its portfolio features significant stakes in pioneering companies such as ATAI Life Sciences and Compass Pathways, which are developing novel treatments for treatment-resistant depression and other mental health conditions. By providing capital and strategic support, Hampstead Private Capital aims to accelerate the development of breakthrough therapies that address significant unmet medical needs.